Cost effectiveness analysis of drotrecogin alfa (activated) as a treatment for severe sepsis in hospitalised patients

被引：0
作者：
R Launois
L Riou Franca
B Guidet
P Aegerter
X Huet
P Meshaka
P Pinton
机构：
[1] REES France,Biostatistique et Informatique médicale
[2] Réseau d'Evaluation en Economie de la Santé,undefined
[3] Hôpital Saint Antoine,undefined
[4] Hôpital Ambroise Paré,undefined
[5] Laboratoire Lilly France,undefined
来源：
Critical Care | / 6卷 / Suppl 1期
关键词：
Severe Sepsis; Cost Effectiveness Ratio; Expected Cost; Drotrecogin Alfa; Differential Cost;
D O I：
10.1186/cc1570
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
[21]   Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis [J].
Barie, PS ;
Williams, MD ;
McCollam, JS ;
Bates, BM ;
Qualy, RL ;
Lowry, SF ;
Fry, DE .
AMERICAN JOURNAL OF SURGERY, 2004, 188 (03) :212-220
[22]   The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes [J].
Greg Martin ;
Frank M Brunkhorst ;
Jonathan M Janes ;
Konrad Reinhart ;
David P Sundin ;
Kassandra Garnett ;
Richard Beale .
Critical Care, 13
[23]   Variable efficacy of drotrecogin alfa (activated) in severe sepsis and septic shock: a meta-analysis [J].
Zhang, Da-Long ;
Zhu, Hui-Yun ;
Zhang, Shuai ;
Wu, Qing-Qing ;
Zhang, Wan-Jiang .
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 10 (09) :12976-12985
[24]   Drotrecogin alfa: a new approach in the treatment of severe sepsis [J].
Vincent, JL .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2002, 2 (06) :659-664
[25]   Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation [J].
Dhainaut, JF ;
Yan, SB ;
Joyce, DE ;
Pettilä, V ;
Basson, B ;
Brandt, JT ;
Sundin, DP ;
Levi, M .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (11) :1924-1933
[26]   Severe sepsis and drotrecogin alfa (activated) use: results from the PROGRESS registry [J].
R Beale ;
F Brunkhorst ;
G Martin ;
M Williams ;
D Nelson ;
J Janes .
Critical Care, 11 (Suppl 2)
[27]   Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice? [J].
M Zia Sadique ;
Richard Grieve ;
David A Harrison ;
Brian H Cuthbertson ;
Kathryn M Rowan .
Critical Care, 15
[28]   Should patients with severe sepsis receive drotrecogin alfa? [J].
Reactions Weekly, 2005, 1072 (1) :5-5
[29]   Comprehensive safety analysis of concomitant drotrecogin alfa (activated) and prophylactic heparin use in patients with severe sepsis [J].
Levy, Mitchell ;
Levi, Marcel ;
Williams, Mark D. ;
Antonelli, Massimo ;
Wang, Dazhe ;
Mignini, Mariano Alejandro .
INTENSIVE CARE MEDICINE, 2009, 35 (07) :1196-1203
[30]   Comprehensive safety analysis of concomitant drotrecogin alfa (activated) and prophylactic heparin use in patients with severe sepsis [J].
Mitchell Levy ;
Marcel Levi ;
Mark D. Williams ;
Massimo Antonelli ;
Dazhe Wang ;
Mariano Alejandro Mignini .
Intensive Care Medicine, 2009, 35 :1196-1203
12345